Cheng Junyun, Chen Jie, Liao Jie, Wang Tianhao, Shao Xin, Long Jinbo, Yang Penghui, Li Anyao, Wang Zheng, Lu Xiaoyan, Fan Xiaohui
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Future Health Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, Zhejiang, 314100, China.
J Pharm Anal. 2023 Apr;13(4):376-387. doi: 10.1016/j.jpha.2023.02.009. Epub 2023 Feb 23.
(PG) and (PN) are highly valuable Chinese medicines (CM). Although both CMs have similar active constituents, their clinical applications are clearly different. Over the past decade, RNA sequencing (RNA-seq) analysis has been employed to investigate the molecular mechanisms of extracts or monomers. However, owing to the limited number of samples in standard RNA-seq, few studies have systematically compared the effects of PG and PN spanning multiple conditions at the transcriptomic level. Here, we developed an approach that simultaneously profiles transcriptome changes for multiplexed samples using RNA-seq (TCM-seq), a high-throughput, low-cost workflow to molecularly evaluate CM perturbations. A species-mixing experiment was conducted to illustrate the accuracy of sample multiplexing in TCM-seq. Transcriptomes from repeated samples were used to verify the robustness of TCM-seq. We then focused on the primary active components, saponins (PNS) and saponins (PGS) extracted from PN and PG, respectively. We also characterized the transcriptome changes of 10 cell lines, treated with four different doses of PNS and PGS, using TCM-seq to compare the differences in their perturbing effects on genes, functional pathways, gene modules, and molecular networks. The results of transcriptional data analysis showed that the transcriptional patterns of various cell lines were significantly distinct. PGS exhibited a stronger regulatory effect on genes involved in cardiovascular disease, whereas PNS resulted in a greater coagulation effect on vascular endothelial cells. This study proposes a paradigm to comprehensively explore the differences in mechanisms of action between CMs based on transcriptome readouts.
人参(PG)和太子参(PN)是极具价值的中药。尽管这两种中药具有相似的活性成分,但其临床应用却明显不同。在过去十年中,RNA测序(RNA-seq)分析已被用于研究提取物或单体的分子机制。然而,由于标准RNA-seq中的样本数量有限,很少有研究在转录组水平上系统地比较PG和PN在多种条件下的作用效果。在此,我们开发了一种方法,即使用RNA测序(中药测序,TCM-seq)对多个样本的转录组变化进行同步分析,这是一种用于分子评估中药干扰作用的高通量、低成本工作流程。进行了一项物种混合实验以说明TCM-seq中样本多重分析的准确性。使用重复样本的转录组来验证TCM-seq的稳健性。然后,我们聚焦于分别从PN和PG中提取的主要活性成分,即人参皂苷(PNS)和太子参皂苷(PGS)。我们还使用TCM-seq对10种细胞系进行了表征,这些细胞系用四种不同剂量的PNS和PGS处理,以比较它们对基因扰动作用、功能途径、基因模块和分子网络的差异。转录数据分析结果表明,各种细胞系的转录模式明显不同。PGS对参与心血管疾病的基因表现出更强的调节作用,而PNS对血管内皮细胞产生更大的凝血作用。本研究提出了一种基于转录组读数全面探索中药作用机制差异的范例。